Dynamics of natural immunity caused by subclinical infections, case study on Haemophilus influenzae type b (Hib)

Epidemiology and Infection

Volumn 125, Issue 3, 2000, Pages 583-591

  Leino, T ^a   Auranen, K ^b   Makela P H ^a   Kayhty H ^a   Takala, A K ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; CASE STUDY; COHORT ANALYSIS; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNITY; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VACCINATION; POPULATION; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; IMMUNITY, NATURAL; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, STATISTICAL; VACCINES, CONJUGATE;

EID: 0034487059     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268800004799     Document Type: Article

References (45)

1. A hierarchical Bayesian model to predict the duration of immunity to Hib
2. Epidemiology of invasive Haemophilus influenzae type b disease
3. Conjugate vaccines and the carriage of Haemophilus influenzae type b
4. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugated vaccine
5. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugated vaccine
6. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b
7. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccine
8. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children
9. Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: Current status and priority actions
10. Vaccines against Haemophilus influenzae type b
11. Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b
12. Induction of serum Haemophilus influenzae type b capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5
13. Meningitis caused by Haemophilus influenzae in infant rats: Protective immunity and antibody priming by gastrointestinal colonization with Escherichia coli
14. Nature of cross-reactivity between Haemophilus influenzae types a and b and Streptococcus pneumoniae types 6A and 6B
15. Quantitative measurement of 'natural' and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies
16. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b
17. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b
18. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin
19. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats
20. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccine
21. Half-life of the maternal IgG1 allotype in infants
22. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia
23. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to re-immunization: No evidence of immunological tolerance or memory
24. Comparison of naturally acquired and vaccine-induced antibodies to Haemophilus influenzae type b capsular polysaccharide
25. Antibody response to capsular polysaccharide of groups A and C Neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease
26. Immunity to disease casued by Haemophilus influenzae type b II. Specificity and some biological characteristics of 'natural', infection-acquired, and immunization-induced antibodies to the capsular influenzae type b
27. Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100 000 vaccinees 3 months to 5 years of age in Finland
28. Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine
29. The humoral immune response to Haemophilus influenzae type b: A mathematical model based on T-zone and germinal center B-cell dynamics
30. Hepatitis B vaccination: How long does the protection last?
31. Hepatitis B vaccination how long does protection last?
32. Timing of booster doses of hepatitis B vaccine
33. Decline of anti-HBs after hepatitis B vaccination and timing of revaccination
34. Long-term immunity to diphtheria and tetanus: A mathematical model
35. Scheduling of revaccination against hepatitis B virus
36. Pharyngeal carriage and acquisition of anticapsular antibody to Haemophilus influenzae type b in a high-risk population in Southwest Alaska
37. Immunity to Haemophilus influenzae type b on sample population from central Italy
38. Mathematical models of Haemophilus influenzae type b
39. Heteroimmunization to the capsular polysaccharide of Haemophilus influenzae type b induced by enteric cross-reacting bacteria
40. Association between cross-reacting Escherichia coli K100 and disease caused by Haemophilus influenzae type b
41. Modeling malaria vaccines. II. Population effects of stage-specific malaria vaccines dependent on natural boosting
42. The Hib immunisation programme in the Oxford region: An analysis of the impact of vaccine administration on the incidence of disease